DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE DETERMINATION OF ALVIMOPAN IN RAT PLASMA
Objective: The present investigation demonstrates a simple, sensitive and accurate high pressure liquid chromatographic (HPLC) method for the determination of alvimopan (AMP) in rat plasma.
Methods: The chromatographic separation was achieved within 10 min by using acetonitrile: potassium dihydrogen phosphate buffer pH 3.0 adjusted with orthophosphoric acid (50:50) as mobile phase on Altima Grace Smart C-18 column (5Î¼; 250 Ã— 4.6 mm) at a flow rate of 1.0 ml/min with injection volume 50 Âµl. The drug was extracted from plasma by liquid-liquid extraction using a mixture of methanol: acetonitrile (50:50) as a solvent. The retention times of drug and internal standard were found to be 5.17 and 6.74 min, respectively. This method was validated as per the United States Food and Drug Administration (US-FDA) guidelines.
Results: The results of the validation parameters were found to be within the acceptance limits. The method was linear in the concentration range from 5-1000 ng/ml (r2= 0.9998), and the extraction recovery was found to be 78.71Â±3.86% for AMP. The lower limit of quantification was found to be 5ng/ml, and the stability of recovered samples at different conditions was found to be more than 95%.
Conclusion: The developed method possess good selectivity, specificity, there was no interference found in the plasma blanks at retention times of AMP and Internal Standard (IS). We found a good correlation between the peak area and concentration of the drug under prescribed conditions. Furthermore, the method can also be used to estimate the pharmacokinetic parameters of AMP.
Keywords: Alvimopan, Liquid-liquid extraction, Method development, Matrix effect, Plasma, Recovery, Stability, Validation
2. FDA press release-FDA Approves Entereg to Help Restore Bowel Function Following Surgery. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2008/ucm116899.htm. [Last accessed on 05 Jul 2018]
3. Alvimopan Product Label as approved by the FDA; 2008.
4. Neary P, Delaney P. Alvimopan. Expert Opin Invest Drugs 2005;14:47988.
5. Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surgery 2001;182(5A):27S-38S.
6. Vrushali ST, Deodhar MN, Vijayalakshmi Prakya LC. LC-MS study for simultaneous determination of tramadol hydrochloride and ketorolac tromethamine in bulk and formulation with major degradation products. Bull Faculty Pharm Cairo University 2016;54:87-97.
7. Essam Ezzeldin, Nisreen F Abo-Talib, Marwa H Tammam, Abdelaaty A Shahat. Development and validation of LC/MS/MS method for the determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study. Chem Central J 2014;8:17.
8. Jaivik V Shah, Priyanka A Shah, Mallika Sanyal, Pranav S Shrivastav. Fast and sensitive LC-MS/MS method for simultaneous determination of lisinopril and hydrochlorthiazide in human plasma. J Pharm Anal 2017;7:163-9.
9. Tejas Dadhaniya, Komal Chaudhary, Priti Mehta. Development of LC-MS/MS method for determination of iloperidone in rabbit plasma: application to pharmacokinetic study. Int J Pharm Pharm Sci 2015;7:294-7.
10. Ravi S Orugunti, H Rush A Strong, E Wells. Quantitative determination of Alvimopan in human plasma by LC-MS-MS. Worldwide Clinical Trials Drug Development Solutions-Bioanalytical Sciences, Austin, Texas; T2296.
11. Addanki Padmini, Sudharani Utala, Gumparthi Prasad, Adigarla Bennayyanaidu, Koyyuri Raju, Rambabu Kuchi. A new L. C. method development and validation for analysis of atvimopin in formulations. Res Desk 2012;1:60-5.
12. US Department of health and human sciences. Food Drug Administration, Guidance for industry, Bioanalytical method development, and validation, U. S. Food Drug Administration, Center for Drug Evaluation and Research; 2001.
13. International Conference on Harmonization (ICH). Validation of Analytical Methods: Methodology. ICH Q2 B; 1996.
14. Matuszewski BK, Constanzer ML, Chavez Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS. Anal Chem 2003;75:3019-30.
15. Nicola CH, Navgeet B, Ernest YKW. Assessing the matrix effects of hemolysed blood in bioanalysis. Bioanalysis 2009;1:1057-66.
16. USP (The United States pharmacopoeia convention) 30-NF 25, Rockville MD; 2007. p. 1005, 1776.